COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update13/11/2018
-   
  Sol-Gel Technologies Reports Third Quarter 2018 Financial Results13/11/2018
-   
  aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update13/11/2018
-   
  Guardant Health To Report Third Quarter Financial Results on November 19, 201813/11/2018
-   
  OpGen Reports third quarter 2018 Financial Results and Provides Business Update13/11/2018
-   
  iCAD Reports Third Quarter 2018 Financial Results13/11/2018
-   
  Imprimis Pharmaceuticals Announces Third Quarter 2018 Results13/11/2018
-   
  Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update13/11/2018
-   
  CareDx Announces Proposed Public Offering of Common Stock13/11/2018
-   
  IntelGenx Closes Private Placement Financing13/11/2018
-   
  Synergy CHC Corp. Announces Third Quarter 2018 Results13/11/2018
-   
  Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the Joint Terms of Merger13/11/2018
-   
  Fusion entre Eckert & Ziegler BEBIG SA (BEBIG) et Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Annonce du dépôt du projet commun de fusion transfrontalière (Projet Commun de Fusion)13/11/2018
-   
  Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer13/11/2018
-   
  Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program13/11/2018
-   
  Dermatologists Urge Consumers to Treat Acne Early; American Academy of Dermatology13/11/2018
-   
  Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference13/11/2018
-   
  Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff13/11/2018
-   
  RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors13/11/2018
Pages